B
Bull
Bull · 25%CLNN
$2.03
Szenariopreis
$4.105
-0.168 (-4.09%)Zum Schluss
Loading chart…
- High
- 4.420
- Open
- 4.220
- VWAP
- 4.18
- Vol
- 159.07K
- Mkt Cap
- 47.39M
- Low
- 4.020
- Amount
- 665.19K
- EV/EBITDA, TTM
- -0.05
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
AI analysis of Clene Inc (CLNN)
buyClene Inc. is a good buy right now due to its current price of $4.23, which is significantly lower than analyst price targets of $30 and $50, indicating a potential upside of over 600%. Additionally, the company has a gross margin of 60% in Q2 2026, suggesting strong profitability potential if revenue generation improves. The main risk is the negative sentiment surrounding its drug application, with analysts expressing skepticism about approval, which could impact stock performance.
Bewertungskennzahlen
The current forward P/E ratio for Clene Inc (CLNN) is 0.00, compared to its 5-year average forward P/E of -2.86.
Alphio AI Price Scenarios for CLNN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
1.008-18NewsfilterSchedule Released for 95th Emerging Growth Conference
- 1.008-17Newsfilter
Clene Inc. to Present at Emerging Growth Conference
- 9.008-14Newsfilter
Clene Plans to Submit NDA for CNM-Au8 in ALS
1.007-29GlobenewswireClene Inc. to Present at Canaccord Growth Conference
- 1.007-29Newsfilter
Clene Inc. to Present at Canaccord Growth Conference in Boston
CLNN FAQ — answered by Alphio AI
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Clene Inc. is a good buy right now due to its current price of $4.23, which is significantly lower than analyst price targets of $30 and $50, indicating a potential upside of over 600%. Additionally, the company has a gross margin of 60% in Q2 2026, suggesting strong profitability potential if revenue generation improves. The main risk is the negative sentiment surrounding its drug application, with analysts expressing skepticism about approval, which could impact stock performance.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.